B2iDigital
Oct 21, 4:19 PM
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:
$LABT ) is presenting research on the in vitro antimicrobial profile of Nu-3, the company's lead clinical candidate, at IDWeek 2026, taking place October 21-24, 2026, in Washington, D.C. The poster is in the Novel Agents session on October 22 from 12:15 to 1:30 PM ET in Poster Hall B-C.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
The poster's in vitro data demonstrate broad-spectrum and rapid bactericidal activity for Nu-3, along with a favorable resistance profile in serial-passage testing:
• Bactericidal activity against Gram-positive, Gram-negative and multidrug-resistant bacteria
• Bacterial eradication occurring within minutes for tested pathogens, as well as activity against biofilm organisms
• Only a slight increase in minimum inhibitory concentration (MIC) values against Staphylococcus aureus and Escherichia coli, compared with a 600- to 2,000-fold increase for ciprofloxacin
"The data being presented at IDWeek reinforce the potential of Nu-3 to play an important role in addressing the growing threat of antimicrobial resistance," said Chief Executive Officer Kelvin Cooper, Ph.D.
Read the full release: https://lakewoodamedex.investorroom.com/2026-10-21-Lakewood-Amedex-Biotherapeutics-Presents-Data-Highlighting-Nu-3s-Broad-Spectrum-Antimicrobial-Activity-and-Low-Potential-for-Resistance-at-IDWeek-2026
These findings are relevant to infected diabetic foot ulcer (iDFU), where approximately half of diabetic foot ulcers become infected and an estimated 15% to 25% involve resistant organisms, primarily methicillin-resistant Staphylococcus aureus (MRSA). Nu-3 is currently being investigated in an ongoing Phase 2a clinical trial in patients with infected diabetic foot ulcers, with topline data expected in the first quarter of 2027.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted LABT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
$SPRO,
$CDTX,
$SCYX,
$XBI
